Sickle Cell Disease Treatment Market Report 2026

Sickle Cell Disease Treatment Market Overview

• Sickle Cell Disease Treatment market size has reached to $3.51 billion in 2025 • Expected to grow to $7.99 billion in 2030 at a compound annual growth rate (CAGR) of 18.1% • Growth Driver: Increasing Blood And Bone Marrow Transplants Fuel Growth In The Sickle Cell Disease Treatment Market • Market Trend: Advancements in Sickle Cell Disease Treatment: Akums Introduces Affordable, Room Temperature-Stable Hydroxyurea Oral Suspension • North America was the largest region in 2025.

What Is Covered Under Sickle Cell Disease Treatment Market?

Sickle cell disease (SCD), also known as sickle cell anemia, is a genetic disorder affecting hemoglobin, a protein in red blood cells. A mutation in the hemoglobin gene causes the production of defective hemoglobin, referred to as hemoglobin S (HbS), in people with sickle cell disease. The sickle cell disease treatment removes blockages, enhances blood flow and repairs damaged tissues. The main types of treatment modalities for sickle cell disease treatment are blood transfusion, pharmacotherapy and bone marrow transplant. The transfer of blood or blood products from a donor to a recipient is known as a blood transfusion. The various disease types are sickle cell anemia, hemoglobin sickle C disease (HBsC) and others with various routes of administration such as oral and parenteral. The end users are hospitals, specialty clinics and others.

What Is The Sickle Cell Disease Treatment Market Growth Forecast?

The sickle cell disease treatment market size is expected to see rapid growth in the next few years. It will grow to $7.99 billion in 2030 at a compound annual growth rate (CAGR) of 18.1%. The growth in the forecast period can be attributed to emergence of gene therapy solutions, expansion of biologics and targeted drugs, integration of predictive diagnostics, increase in global healthcare initiatives, personalized treatment plans for patients. Major trends in the forecast period include development of gene-editing therapies, increasing availability of hydroxyurea, expansion of blood transfusion management, adoption of advanced diagnostics for early detection, growth in patient support and disease management programs.

Global Sickle Cell Disease Treatment Market Segmentation

1) By Treatment Modality: Blood Transfusion, Pharmacotherapy, Bone Marrow Transplant 2) By Disease Type: Sickle Cell Anemia, Hemoglobin Sickle C Disease (HbSC), Other Disease Types 3) By Route Of Administration: Oral, Parenteral 4) By End-User: Hospitals, Specialty Clinics, Other End-Users Subsegments: 1) By Blood Transfusion: Regular Blood Transfusion, Exchange Transfusion 2) By Pharmacotherapy: Hydroxyurea, L-Glutamine, Voxelotor, Crizanlizumab 3) By Bone Marrow Transplant: Allogeneic Transplant, Autologous Transplant

What Is The Driver Of The Sickle Cell Disease Treatment Market?

The rising blood and bone marrow transplant is expected to propel the growth of sickle cell disease treatment going forward. A blood and bone marrow transplant is a medical procedure that replaces unhealthy blood-forming cells with healthy ones. A bone marrow transplant aims to cure sickle cell diseases and cancers by infusing healthy bone marrow cells into a person after their sick bone marrow has been treated to remove the abnormal cells. The replacement cells are derived from the patient's own body (autologous transplant) or from a donor's body (allogeneic transplant). For instance, in June 2024, according to the National Transplant Organization (ONT), a Spain-based independent coordinating agency, in 2023, Spain added 23,686 donors to the Spanish Bone Marrow Donor Registry, an 8% increase from 2022, and achieved a record 3,717 hematopoietic stem cell transplants, equating to 77.4 transplants per million population. Thus, the rising blood and bone marrow transplant will boost the sickle cell disease treatment industry.

Key Players In The Global Sickle Cell Disease Treatment Market

Major companies operating in the sickle cell disease treatment market are Sun Pharmaceutical Industries Ltd., Pfizer Inc., Johnson & Johnson Private Limited, Merck & Co Inc., Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Global Blood Therapeutics Inc., Acceleron Pharma Inc., Sangamo Therapeutics Inc., Medunik USA Inc., Zydus Cadila Healthcare Ltd., Graphite Bio Inc., Addmedica, Emmaus Medical Inc., Bluebird bio Inc., CRISPR Therapeutics AG, GlycoMimetics Inc., Mast Therapeutics Inc.

Global Sickle Cell Disease Treatment Market Trends and Insights

Major companies operating in the sickle cell disease treatment market are focusing on developing new oral suspension drugs to improve patient compliance, enhance drug efficacy, and provide more convenient treatment options, especially for pediatric and elderly patients. Oral suspension drugs are liquid medications with solid particles mixed in a liquid, designed to make swallowing easier for patients, particularly children or those who struggle with pills. For instance, in March 2024, Akums Drugs and Pharmaceuticals Ltd., a India-based pharmaceutical preparation manufacturing company, launched a room temperature-stable oral suspension of Hydroxyurea. This medication for SCD is an affordable, room-temperature-stable treatment designed to increase accessibility in India. Priced at less than 1% of imported options, it offers precise dosing with oral syringes, benefiting patients of all ages without requiring cold storage.

What Are Latest Mergers And Acquisitions In The Sickle Cell Disease Treatment Market?

In December 2023, Vertex Pharmaceuticals, a US-based biopharmaceutical company, partnered with Editas Medicine to leverage Editas’s Cas9 gene‑editing technology to develop ex vivo therapies (notably CASGEVY) for sickle cell disease and beta thalassemia, accelerating its precision gene-therapy pipeline. Editas Medicine is a US-based provider of CRISPR/Cas9 and Cas12a genome-editing platforms for therapeutic applications.

Regional Outlook

North America was the largest region in the sickle cell disease treatment market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Sickle Cell Disease Treatment Market?

The sickle cell disease treatment market consists of revenues earned by entities by providing services such as oxygen therapy, pulmonary hypertension management and pain management. The market value includes the value of related goods sold by the service provider or included within the service offering. The sickle cell disease treatment market also includes sales of hydroxyurea, L-glutamine and voxlelotor. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Sickle Cell Disease Treatment Market Report 2026?

The sickle cell disease treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the sickle cell disease treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.